Abstract
INTRODUCTION
In conditions with macrophage proliferation and acti vation, CD163, a haemoglobinhaptoglobin scavenger receptor expressed exclusively on monocytes and macrophages [1, 2] , is upregulated [3, 4] . Following tolllike receptor activation by inflammatory stimuli like lipopoly saccharide (LPS), receptor shedding to circulation as soluble CD163 (sCD163) is increased, and within hours upregulated on the cell surface [5] . As an example, hepatic macrophages (Kupffer cells) are activated and sCD163 is increased in patients with liver cirrhosis who chronically experience some degree of endotoxemia and acute phase response [6, 7] and this may be involved in the development of the serious cirrhosis complications [6, 8] . We have recently constructed a conjugate of CD163 antibody and the potent corticosteroid dexamethasone (antiCD163mAbdexa) specifically targeting dexa methasone to activated macrophages [9] . The conjugate reduces the LPSstimulated cytokine release from activated macrophages in vitro and in vivo in rats and pigs [9, 10] . The effect is obtained with very low con centration of dexamethasone, thereby minimizing steroidinduced systemic effects. A fiftyfold higher con centration of nonconjugated dexamethasone is needed to obtain the same antiinflammatory response [9] . Exposure to LPS is a standard method to induce an acute phase response with a large increase in pro inflammatory cytokines and hepatic synthesis and release of acute phase proteins [11, 12] . While the conjugate reduces the LPSmediated cytokine response in rats it remains unknown whether it also inhibits the hepatic acute phase protein synthesis response.
To approach this issue we measured the gene expression in liver tissue and serum concentrations of the prevailing acute phase protein a2macroglobulin (a2M) 24 h postLPS exposure in rats. a2M is a hepatocytederived inhibitor of a wide range of pro teinases that can be activated during inflammation [13] . Further, we compared plasma concentrations of tumour necrosis factora (TNFa) and interleukin 6 (IL6) 2 h postLPS exposure. Spleen weight served as an indicator of systemic steroid effects.
MATERIALS AND METHODS

Animals
The animal protocol was designed to minimize pain or discomfort to the animals. Female Wistar rats (body weight 190210 g; Taconic M and B, Ejby, Denmark) were housed at 21 ℃ ± 2 ℃ with a 12h artificial light cycle. Two or three animals were housed in each cage, with free access to tap water and standard food (Altromin, Lage, Germany) and acclimatized for one week. Food intake and body weight were registered at the beginning and at the end of the experimental procedures. The study was performed in accordance with local and national guidelines for animal welfare and approved by the national Animal Ethics Committee, protocol No. 2010/5611918.
Design
Forty animals were allocated in 5 groups of 8: One control group receiving only vehicle (PBS pH 7.4) intra venously and four groups injected intravenously with either vehicle, antiCD163mAbdexa (0.02 mg/kg dexamethasone), high dose free dexamethasone (1 mg/kg) (SigmaAldrich, Brøndby, Denmark), or low dose free dexamethasone (0.02 mg/kg). The high ("therapeutic") dose gives maximal steroid efficacy in other rat studies [14, 15] and the low dose was the same as in the antiCD163mAbdexa. After 24 h, 0.5 mL of saline (controls) or LPS dissolved in 0.5 mL saline (2.5 mg/kg) (from Ecsherichia coli 0111:B4 obtained from Sigma Aldrich, Brøndby, Denmark; product No. L2630) was injected intraperitoneally. Two hours later and following anaesthesia with inhalation of isofluran 2%3% (Forene ® , Abbott Laboratories, Gentofte, Denmark), a blood sample for determination of plasma TNFa and IL6 was drawn from a retrobulbary venous plexus using heparinised micropipettes. After an overnight 12h fast the animals were anaesthetised with a subcutaneous injection of fentanyl/fluanisone (Hypnorm ® , Jansen Pharma, Birkerød, Denmark) 0.5 mL/kg and midazolam (Dormicum ® , La Roche, Basel, Schwitzerland) 2.5 mg/kg. All blood was collected for blood analyses and approximately 200 mg of liver tissue was snapfrozen in liquid N2, and stored at 80 ℃. Finally, the spleen was weighed. In all animals we measured liver mRNA levels and serum concentrations of a2M and plasma concentrations of alanine aminotransferase and bilirubin at termination of the study.
Liver tissue
mRNA levels of a2M were determined by slot blot hybridization as previously described [16] .
Blood analyses
The concentrations of a2M in serum were evaluated by rat ELISA (Immunology Consultants Laboratory, Newberg, OR, United States). The plasma concentrations of TNFa and IL6 were determined by immunoassay (R and D Systems, Minneapolis, MN, United States, both). Samples were analysed in duplicate and all assays had intra and interassay coefficients of variance below 5% and 10%, respectively. Plasma concentrations of alanine aminotransferase and bilirubin were determined by standard clinical biochemical analytical methods.
Statistical analysis
Data were analysed using the KruskalWallis One Way Analysis of Variance on Ranks; when significant, post hoc tests were performed among groups by the Mann Whitney rank sum test. Data are presented as the mean ± SEM. Differences were considered significant with Pvalues < 0.05. A statistical review of the study was performed by a biomedical statistician.
RESULTS
Body and spleen weight
LPS induced a body weight loss in all the intervention groups (P < 0.05) ( Table 1) and there was no difference among these groups. The high dose dexamethasone dose decreased the spleen weight (P < 0.05), an effect not seen in any other group (Table 1) .
Acute phase protein liver mRNA and serum levels LPS increased the liver mRNA and serum levels of a2M several fold in all groups (P < 0.01) (Figure 1) . AntiCD163mAbdexa approximately halved the a2M liver mRNA (P < 0.01) and serum response (P = 0.04) compared to low dose dexamethasone treated animals, while no free dexamethasone dose had any effect on liver mRNA or serum levels of a2M compared to vehicle (Figure 1 ).
TNF-a and IL-6
LPS markedly increased plasma TNFa and IL6 in all groups (P < 0.001). There was a trend for reduced TNFa (P = 0.08) after antiCD163mAbdexa compared to vehicle and significantly so vs the low dose dexame thasone (P = 0.03). Also, the antiCD163mAbdexa decreased IL6 compared to both dexamethasone doses (P < 0.05). None of the free dexamethasone doses had Body weight (g), body weight loss (g), spleen weight (mg), plasma alanine aminotransferase (U/L), and bilirubin (μmol/L) in controls (n = 8) and in animals injected with LPS 24 h after vehicle (n = 8), anti-CD163mAb-dexa (n = 8), high dose (n = 8) and low dose (n = 8) dexamethasone at termination of study. Plasma TNF-a (pg/mL) and IL-6 (pg/mL) are measured 2 h after saline (controls) or LPS injection. a P < 0.05 vs controls; c P < 0.05 vs low dose free dexamethasone group; e P < 0.05 vs high dose free dexamethasone group; g P < 0.05 vs vehicle. ALT: Alanine aminotransferase; TNF-a: Tumor necrosis factor-a; IL-6: Interleukin-6; LPS: Lipopolysaccharide.
phages [19] . However, as glucocorticoids bind to the ubiquitous intracellular glucocorticoid steroid receptor present in most cell types they also exert serious systemic metabolic side effects. Thus dexamethasone causes the spleen to undergo a corticosteroidinduced weight reduction due to lymphocyte depletion [20] .
Accordingly, the high dose dexamethasone in our study decreased the spleen weight as compared with the other groups reflecting systemic nonmacrophages effects. In contrast, the conjugate did not affect spleen weight and was still found to exert a potent antiinflammatory effect. In our animal model, the conjugate was given as a preemptive dose prior to the induction of the acute phase response as we aimed at establishing a proofof concept position of the conjugate's effects. We believe our findings support further studies on interference with ongoing inflammation in relevant experimental models. Such studies are also essential for monitoring of long term effects of the conjugate.
In conclusion, the antiCD163dexa conjugate de monstrated potent effects in reducing the acute phase proteins without evident systemic side effects during an endotoxininduced acute phase response in rats. The effect much exceeded that of a therapeutic dose of dexamethasone. Thus, the antibody conjugate may be a potential candidate in future antiinflammatory macrophagedirected therapy, e.g., in liver diseases with Kupffer cells activation [7] .
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Background
In conditions with macrophage proliferation and activation, CD163, a scavenger an effect on TNFa or IL6 (Table 1) .
Plasma-alanine transferase and bilirubin
LPS had no effect on these measures at termination of the study (Table 1) .
DISCUSSION
The central finding of this study was the reduction in liver mRNA and plasma a2M, and plasma TNFa and IL6 by the administration of the antiCD163 dexa conjugate prior to the LPSinduced inflammatory response. This antiacute phase effect much exceeded that of the therapeutic dexamethasone dose and did not cause systemic adverse effects, as evidenced by reduced spleen weight in the group treated with high dose free dexamethasone. This study completes the chain of evidence that the conjugate not only suppresses the LPS elicited IL signaling but also the ultimate effect on synthesis and release of hepatic acute phase proteins that effectuate the acute phase response.
The increase in plasma a2M after LPS reflects de novo synthesis as almost no such protein is pre sent under noninduced conditions [17] in contrast to conditions with ongoing low grade inflammation such as cirrhosis [18] . LPS as assumed caused a marked systemic acute phase response reflected in increased liver mRNA and plasma a2M, TNFa, and IL6. In contrast to the equal amount of free dexamethasone, the anti CD163mAbdexa efficiently suppressed this response. Still, however, the acute phase response to some extent serves to restore homeostasis and one needs to be aware that suppression of the response might not be entirely beneficial entailing a potential risk using the conjugate long term.
The antiinflammatory effects of glucocorticoids are related to a decrease in lymphocyte expansion and cell survival and also a reduction in the expression of proinflammatory cytokines originating from macro 
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